The Launch Angle

RevHealth

Every successful launch has a story that rarely gets told. Launch Angle is a podcast about the real decisions behind successful pharmaceutical and biotech commercialization. Hosted by William Martino, Chief Commercial Officer, and Ben Beckley, CEO of RevHealth, each episode features candid conversations with experienced commercial leaders who have navigated high-stakes launches, compressed timelines, competitive markets, and the countless tradeoffs that determine success. Rather than simply asking what happened, we explore why—the critical decisions, unexpected challenges, lessons learned, and moments that changed the trajectory of a launch. As artificial intelligence reshapes the way therapies are developed, marketed, and brought to patients, we also ask an important question: How would these launches be different if they happened today? Whether you're preparing for your first launch or your tenth, Launch Angle offers practical insight from the people who've been there—and a fresh perspective on where commercialization is headed next.

About

Every successful launch has a story that rarely gets told. Launch Angle is a podcast about the real decisions behind successful pharmaceutical and biotech commercialization. Hosted by William Martino, Chief Commercial Officer, and Ben Beckley, CEO of RevHealth, each episode features candid conversations with experienced commercial leaders who have navigated high-stakes launches, compressed timelines, competitive markets, and the countless tradeoffs that determine success. Rather than simply asking what happened, we explore why—the critical decisions, unexpected challenges, lessons learned, and moments that changed the trajectory of a launch. As artificial intelligence reshapes the way therapies are developed, marketed, and brought to patients, we also ask an important question: How would these launches be different if they happened today? Whether you're preparing for your first launch or your tenth, Launch Angle offers practical insight from the people who've been there—and a fresh perspective on where commercialization is headed next.